97 related articles for article (PubMed ID: 38418234)
1. Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.
Chen M; Huang Y; Zhang S; Zheng Y; Zeng T; Chen C; Zheng B
BMJ Open; 2024 Feb; 14(2):e075421. PubMed ID: 38418234
[TBL] [Abstract][Full Text] [Related]
2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma.
Zhang GL; Zhu QK; Ma TY; Weng CG; Zhang DD; Zeng H; Wang T; Gao F; Mi LL; Wang R
Dis Esophagus; 2024 Apr; 37(4):. PubMed ID: 38189470
[TBL] [Abstract][Full Text] [Related]
4. Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial.
Fan C; Wang X; Zheng X; Sun Y; Ye K; Jiang Y; Liu X; Xu W; Liu Y; Yang Y; Liu J; Jiang Q; He C; Wu X; Nie X; Zhang J; Tan B; Wang W; Zhang Y; Feng Z; Yang C; Lu Y; Liu H; Chen X; Xu J; Liu F; Zheng X; Wang J; Wu S; Chen G; Zhang Y; Jin L; Ge H
BMC Cancer; 2024 Mar; 24(1):321. PubMed ID: 38454345
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
[TBL] [Abstract][Full Text] [Related]
7. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial.
Jia R; Yin W; Li S; Li R; Yang J; Shan T; Zhou D; Wang W; Wan L; Zhou F; Gao S
Trials; 2019 Apr; 20(1):206. PubMed ID: 30971301
[TBL] [Abstract][Full Text] [Related]
10. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.
Hurt CN; Nixon LS; Griffiths GO; Al-Mokhtar R; Gollins S; Staffurth JN; Phillips CJ; Blazeby JM; Crosby TD
BMC Cancer; 2011 Oct; 11():466. PubMed ID: 22035459
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma.
Oshima K; Tsushima T; Ito Y; Kato K
Jpn J Clin Oncol; 2024 Apr; 54(4):395-402. PubMed ID: 38342589
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
[TBL] [Abstract][Full Text] [Related]
14. Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
Shiozaki A; Kudou M; Fujiwara H; Konishi H; Shimizu H; Arita T; Kosuga T; Yamamoto Y; Morimura R; Ikoma H; Kuriu Y; Kubota T; Okamoto K; Otsuji E
Medicine (Baltimore); 2020 Dec; 99(50):e23633. PubMed ID: 33327342
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial.
Wu Z; Wu C; Zhao J; Wu C; Peng H; Wang Q; Bai R; Fang X; He H; Shen H; Wu M
EClinicalMedicine; 2024 May; 71():102579. PubMed ID: 38618203
[TBL] [Abstract][Full Text] [Related]
16. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study.
Roth S; Springfeld C; Diener MK; Tjaden C; Knebel P; Klaiber U; Michalski CW; Mieth M; Jäger D; Büchler MW; Hackert T
BMJ Open; 2019 Aug; 9(8):e028696. PubMed ID: 31434770
[TBL] [Abstract][Full Text] [Related]
17. Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis.
Gao X; Overtoom HCG; Eyck BM; Huang SH; Nieboer D; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Chao YK; van Lanschot JJB
Br J Surg; 2024 May; 111(5):. PubMed ID: 38721902
[TBL] [Abstract][Full Text] [Related]
18. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX; Cui TY; Yang XD; Wang GQ; Jiang QS; Sun H; Jiang NY; Yong XM; Shi CB; Ding YB; Chen XF; Fang YY
Onco Targets Ther; 2021; 14():4859-4865. PubMed ID: 34584426
[TBL] [Abstract][Full Text] [Related]
19. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China.
Yu J; Liu H; Wu Y
BMJ Open; 2024 May; 14(5):e081090. PubMed ID: 38806431
[TBL] [Abstract][Full Text] [Related]
20. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.
Hudson EM; Noutch S; Webster J; Brown SR; Boele FW; Al-Salihi O; Baines H; Bulbeck H; Currie S; Fernandez S; Hughes J; Lilley J; Smith A; Parbutt C; Slevin F; Short S; Sebag-Montefiore D; Murray L
BMJ Open; 2024 Mar; 14(3):e078926. PubMed ID: 38458809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
